I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 21 studies | 19% ± 3% | |
| plasma cell | 19 studies | 37% ± 12% | |
| plasmacytoid dendritic cell | 13 studies | 30% ± 12% | |
| CD16-positive, CD56-dim natural killer cell, human | 9 studies | 25% ± 9% | |
| plasmablast | 8 studies | 38% ± 24% | |
| conventional dendritic cell | 7 studies | 21% ± 5% | |
| IgA plasma cell | 7 studies | 31% ± 9% | |
| CD16-negative, CD56-bright natural killer cell, human | 6 studies | 21% ± 2% | |
| IgG plasma cell | 6 studies | 27% ± 9% | |
| gamma-delta T cell | 5 studies | 21% ± 4% | |
| non-classical monocyte | 4 studies | 25% ± 6% | |
| CD8-positive, alpha-beta T cell | 4 studies | 21% ± 2% | |
| dendritic cell | 4 studies | 23% ± 7% | |
| CD8-positive, alpha-beta memory T cell | 4 studies | 22% ± 2% | |
| monocyte | 3 studies | 30% ± 4% | |
| mature NK T cell | 3 studies | 21% ± 5% | |
| macrophage | 3 studies | 19% ± 2% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
| mucosal invariant T cell | 3 studies | 18% ± 1% |
